Trial Search Results
Methylphenidate Treatment of Attention Deficits in Epilepsy
Methylphenidate (MPH) has long been used to improve attention and cognitive difficulties associated with ADHD, including in children with ADHD and epilepsy (Torres et al., 2008). Methylphenidate (MPH) is also helpful in treating attention and other cognitive difficulties in a variety of other neurological and medical conditions (Kajs-Wyllie, 2002; Prommer, 2012). We seek to evaluate the potential efficacy and safety of this medication in treating attention deficits, as well as other cognitive difficulties, experienced by adult patients with epilepsy.
To our knowledge, there are currently very few studies which explicitly examine the impact of MPH on measureable attention deficits and other cognitive deficits in adult patients with epilepsy. We hope to quantify what impact, if any, methylphenidate has on attention, in addition to other specific measureable cognitive functions, in patients with cognitive complaints and epilepsy, and contribute to a growing body of evidence which supports the safety of methylphenidate's use for attention deficits in patients with epilepsy. As other effective treatments for attention and other cognitive difficulties in patients with epilepsy are not currently available, MPH could represent an important option in the treatment of such patients.
Stanford is currently not accepting patients for this trial.
Kimford Jay Meador
- Drug: Methylphenidate
1. For participants with seizures:
- H/o seizures of any cause
- Subjective cognitive complaints
- Stable antiepileptic drug doses which are not expected to change during the study
- Recent normal cardiac auscultation (may be done prior to enrollment by personal
physician or study staff)
- Neurologist's judgement that participant is clinically appropriate for this study
2. For healthy volunteers
- No history of seizures or other neurological disorders
- No history of cognitive complaints for any reason (including ADHD)
- Not on any medications which would interfere w/ cognitive testing
3. English fluency
2. History of an adverse reaction to methylphenidate
3. Age >65 or <18
4. Personal medical history of
2. Structural cardiac disease,
3. Other cardiac abnormality
4. Uncontrolled hypertension (>150/95) during study. For those with BP >140/90 &
<150/95, they will be monitored during the study and refer them for treatment if
their BP remains elevated throughout the study.
5. Uncontrolled tachycardia during study
6. Progressive neurological disorders which may interfere w/ cognition for reasons
other than seizures
8. Other medical or neurological illnesses or symptoms which may interfere with
cognition or medication (e.g., severe liver or renal disease, active infections,
etc), or which make use of the medication inappropriate (e.g., severe
9. Intellectual disability sufficient to render a participant unable to consent
10. Status epilepticus within the last year
11. Neurosurgery which would be expected to interfere with study tasks within the
last 6 months.
5. Substance use history
1. Met criteria for substance use disorder within the past year
2. Active illicit substance use
3. Alcohol use meeting criteria for substance abuse
4. Unwillingness to abstain from alcohol w/in 24 hours of testing
6. Personal psychiatric history
1. History of a primary psychotic disorder, such as schizophrenia, or mania.
2. History of suicide attempts within the last year
3. Active suicidality
7. Severe cognitive impairments (e.g. aphasia) which render a participant unable to
8. Currently receiving medications which would be expected to interfere with the study
tasks, if they cannot be held for study visits;
9. Pregnancy or active breastfeeding;
10. Women of childbearing potential who are sexually active and not willing or able to use
a contraceptive strategy during the course of the study.
11. Any other factor which may interfere w/ a participant's ability to consent or to
complete the required cognitive tasks, or may significantly interfere with their
performance on the required tests
12. Concomitant use of an MAOI (if receiving methylphenidate during this study), or use of
an MAOI within the last 14 days prior to receiving methylphenidate.
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study